Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 4 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Non-Hodgkin 4 Lymphoma, B-Cell 3 Carcinoma, Non-Small-Cell Lung 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Ovarian Neoplasms 2 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Recurrence 1 Pancreatic Neoplasms 1 Pancreatic Adenocarcinoma 1 Nasopharyngeal Neoplasms 1 Mesothelioma 1 Liver Neoplasms 1 Kidney Neoplasms 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Hepatocellular 1 Burkitt Lymphoma 1 Advanced Liver Cancers 1

Interventions

Dexamethasone 33 Cyclophosphamide 29 venetoclax 18 fludarabine 18 Lenalidomide 16 Bortezomib 16 Cytarabine 13 pembrolizumab 12 Calcium Dobesilate 12 Carboplatin 11 fludarabine phosphate 10 Rituximab 10 pomalidomide 9 Gemcitabine 9 Nivolumab 8 Azacitidine 7 daratumumab 6 carfilzomib 6 blinatumomab 6 Decitabine 6 Bendamustine Hydrochloride 6 selinexor 5 obinutuzumab 5 ibrutinib 5 Vincristine 5 Temozolomide 5 Methotrexate 5 Etoposide 5 Cisplatin 5 tafasitamab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recurrence × tocilizumab × Clear all

NCT05533775 2026-05-04

iMATRIX GLO

Hoffmann-La Roche

Phase 1/2 Recruiting

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡